ClinicalTrials.gg
Not yet recruitingNCT07862725Updated Oct 7, 2026

Comparative Efficacy of Antioxidants Alone Versus Combined Therapy With SERMs or FSH in Normogonadotropic Idiopathic OAT Patients: A Randomized Controlled Trial

A Phase 4 interventional study of Antioxidants + Clomiphene Citrate and Antioxidants + FSH in Oligoasthenoteratozoospermia and Male Infertility, sponsored by Hamad Medical Corporation. Not yet recruiting at 1 site in Qatar. Open to male participants aged 21 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Hamad Medical Corporation · Phase 4, Interventional, and Treatment

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
Male
01

Study summary

This prospective randomized controlled trial will compare three treatment approaches for men with idiopathic oligoasthenoteratozoospermia (OAT), a condition characterized by abnormalities in sperm count, movement, and shape without an identified cause. Participants will be randomly assigned in a 1:1:1 ratio to receive antioxidant therapy alone, antioxidant therapy plus clomiphene citrate, or antioxidant therapy plus follicle-stimulating hormone (FSH) for 6 months.

The study will evaluate whether adding clomiphene citrate or FSH to antioxidant therapy improves semen parameters compared with antioxidant therapy alone. The main outcomes will include changes in sperm concentration, motility, and morphology. The study will also assess sperm function, hormonal changes, treatment adherence, and adverse events.

02

Conditions studied

  • Oligoasthenoteratozoospermia
  • Male Infertility

Keywords

  • Idiopathic infertility
  • Oligoasthenoteratozoospermi
  • Selective estrogen receptor modulators
  • FSH
  • Antioxidants
  • Clomiphene citrate
03

In context

Oligospermia

64 studies on the registry are indexed under Oligospermia; 17 are open to participants now.

This study's planned enrollment of 360 is above the median of 65 across 46 interventional studies indexed under Oligospermia.

Browse Oligospermia studies →

Lead sponsor

Hamad Medical Corporation is the lead sponsor of 139 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients aged 21 to 50 years
  • Diagnosed with idiopathic oligoasthenoteratozoospermia
  • Sperm concentration ≥2 million/mL on at least one semen analysis
  • FSH \<8.0 IU/L
  • Normal serum testosterone
  • Normal karyotypeAbsence of Y-chromosome microdeletions
  • No varicocele or clinically insignificant Grade I varicocele only
  • Ability and willingness to comply with the study protocol and follow-up schedule
  • Provision of written .

Exclusion criteria

Exclusion Criteria:

  • History of cryptorchidism.
  • Previous orchidopexy.
  • Previous testicular torsion.
  • Previous testicular trauma.
  • History of chemotherapy.
  • History of radiotherapy.
  • Previous testicular surgery.
  • Azoospermia.
  • Severe oligospermia with sperm concentration \<2 million/mL.
  • Known genetic abnormalities, including Klinefelter syndrome.
  • Y-chromosome microdeletion.
  • Hormonal treatment for infertility within the previous 6 months.
  • Current use of medications known to affect spermatogenesis, including testosterone or anabolic steroids.
  • Significant medical comorbidities such as liver failure, renal disease, or uncontrolled diabetes. History of varicocelectomy within the previous year.
  • Pyospermia.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Active comparator
    Antioxidants Alone

    Participants will receive antioxidant therapy consisting of vitamin C 1000 mg/day, vitamin E 400 IU/day, L-carnitine, and zinc 25 mg/day for 6 months.

    Drug: Antioxidants + Clomiphene Citrate · Drug: Antioxidants + FSH

  • Experimental
    Antioxidants + Clomiphene Citrate

    Participants will receive the same antioxidant regimen plus clomiphene citrate 50 mg orally every other day for 6 months.

    Drug: Antioxidants + FSH · Drug: Antioxidants Alone

  • Experimental
    Antioxidants + FSH

    Participants will receive the same antioxidant regimen plus FSH 150 IU administered subcutaneously three times weekly for 6 months.

    Drug: Antioxidants + Clomiphene Citrate · Drug: Antioxidants Alone

Interventions

  • DrugAntioxidants + Clomiphene Citrate

    Drug pages: Antioxidants · Clomiphene

    Participants will receive the same antioxidant regimen as the active comparator arm plus clomiphene citrate 50 mg orally every other day for 6 months.

    Also known as: Clomiphene Citrate, Antioxidants

  • DrugAntioxidants + FSH

    Drug pages: Antioxidants · Follicle Stimulating Hormone

    Participants will receive the same antioxidant regimen plus FSH 150 IU administered subcutaneously three times weekly for 6 months.

    Also known as: Antioxidants, follicle-stimulating hormone

  • Participants will receive antioxidant therapy consisting of vitamin C 1000 mg/day, vitamin E 400 IU/day, L-carnitine, and zinc 25 mg/day for 6 months

06

What researchers measure

Primary outcomes

  1. Change in Sperm Concentration

    Change in sperm concentration, measured in million sperm/mL, from baseline to 6 months after initiation of treatment.

    Time frame: Baseline and 6 months

  2. Change in Sperm Motility

    Change in sperm motility, measured as the percentage of motile sperm, from baseline to 6 months after initiation of treatment.

    Time frame: Baseline and 6 months

  3. Change in Sperm Morphology

    Change in normal sperm morphology from baseline to 6 months after initiation of treatment.

    Time frame: from baseline to 6 months

Secondary outcomes

  1. Change in oxidative stress / oxidation-reduction potential

    Change in seminal oxidative stress measured by oxidation-reduction potential (ORP).

    Time frame: Baseline and 6 months

  2. Change in sperm DNA fragmentation

    Change in sperm DNA fragmentation, measured using the study's specified sperm function testing method.

    Time frame: Baseline and 6 months

  3. Change in follicle-stimulating hormone

    Change in serum FSH concentration from baseline to 6 months.

    Time frame: Baseline to 6 months

  4. Change in Luteinizing Hormone

    Change in serum luteinizing hormone (LH) concentration from baseline to 6 months.

    Time frame: From baseline to 6 months.

  5. Change in Testosterone

    Change in serum testosterone concentration from baseline to 6 months.

    Time frame: from baseline to 6 months

  6. Change in Estradiol

    Change in serum estradiol concentration from baseline to 6 months.

    Time frame: baseline to 6 months

  7. Treatment Tolerability and Adverse Events

    Assessment of treatment tolerability and occurrence of adverse events during the treatment period.

    Time frame: From treatment initiation through 6 months

  8. Medication Adherence

    Assessment of adherence to the assigned study treatment during the treatment period.

    Time frame: From treatment initiation through 6 months

07

Study locations

1 site
  • Ambulatory Care Center (ACC), Hamad Medical Corporation
    Doha, Baladiyat ad Dawhah 3050, Qatar
    • Sara Taha Shabana · Contactsshabana@hamad.qa · 55398571
    • Haitham El Bardisi · Principal investigator
    • Nadir Fadol · Sub investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 7, 2026
StartEst.
Oct 15, 2026
Primary completionEst.
Oct 15, 2027
CompletionEst.
Oct 15, 2028
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07862725
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Oct 15, 2026 (estimated)
Primary completion
Oct 15, 2027 (estimated)
Completion
Oct 15, 2028 (estimated)
Last update
Oct 7, 2026

Study contacts

Dr. Haitham Tharwat El-Bardisi
Contact
Helbardisi@hamad.qa
66426664 ext. 00974
Dr. Nadir Ibrahim Fadol
Contact
NFadol1@hamad.qa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Antioxidants · Clomiphene · Follicle Stimulating Hormone

Start the discussion